Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.42 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.41 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | MLYCD | O95822 | 1/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2594613 | 0.82 | KDM4E (0.49) | KDM4ETP53HRH3CHRNA10CHRNA9 | |
| SCHEMBL2594614 | 0.82 | KDM4E (0.49) | KDM4ETP53HRH3CHRNA10CHRNA9 | |
| SCHEMBL6125344 | 0.82 | KDM4E (0.49) | KDM4ETP53HRH3CHRNA10CHRNA9 | |
| Hydrochloric Acid SCHEMBL709248 | 0.81 | KDM4E (0.47) | KDM4ETP53HRH3CHRNA10CHRNA9 | |
| Hydrochloric Acid SCHEMBL709249 | 0.81 | KDM4E (0.47) | KDM4ETP53HRH3CHRNA10CHRNA9 | |
| SCHEMBL4423739 | 0.80 | ADRB1 (0.52) | KDM4EKCNH2 | |
| SCHEMBL16567891 | 0.78 | KDM4E (0.56) | KDM4ETP53HRH3CHRNA10CHRNA9 | |
| SCHEMBL14741020 | 0.78 | KDM4E (0.56) | KDM4ETP53HRH3CHRNA10CHRNA9 | |
| SCHEMBL20346556 | 0.74 | KDM4E (0.65) | KDM4ETP53HRH3CHRNA10CHRNA9 | |
| SCHEMBL6503007 | 0.74 | ALDH1A1 (0.60) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6372762-B1 | HETEROCYCLIC COMPOUNDS FOR NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2002-04-16 | — | — | US | disclosed |
| US-20020019401-A1 | Substituted bicyclic derivatives for treating central nervous system disorders | FLIRI ANTON FRANZ JOSEPH (US) | 2002-02-14 | — | — | US | disclosed |
| EP-0953567-A2 | Bicyclic substituted piperazine-, piperidine- and tetrahydropyridine derivatives, their preparation and their use as agents with central dopaminergic (dopamine D4 receptor) activity | Pfizer Products Inc. (US) | 1999-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019401-A1 | Substituted bicyclic derivatives for treating central nervous system disorders | OPRK1, OPRD1, MC2R | KDM4E 1783/4885TP53 4835/4885HRH3 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.